Session Details
[LS-39]Luncheon Seminar 39 Significance of IL-6 inhibition considering long-term prognosis in NMOSD
Fri. May 23, 2025 12:00 PM - 1:00 PM JST
Fri. May 23, 2025 3:00 AM - 4:00 AM UTC
Fri. May 23, 2025 3:00 AM - 4:00 AM UTC
第13会場(リーガロイヤルホテル大阪3F 光琳の間①)
Chair: Izumi Kawachi（Department of Neurology, Brain Research Institute, Niigata University, Japan／Comprehensive Medical Education Center, Niigata University School of Medicine, Japan）
Sponsored by: Chugai Pharmaceutical Co., Ltd.
[LS-39-1]The immunology of NMOSD
Sarosh R. Irani (Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA)
[LS-39-2]How Satralizumab changed treatment strategy in NMOSD- Real World Evidence from Japan -
Kazuo Fujihara (Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine／Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan)